Roche, Pacific Biosciences seal $75M clinical Dx partnership

Struggling gene sequencer Pacific Biosciences ($PACB) signed a diagnostics product-development deal with industry giant Roche ($RHHBY) worth as much as $75 million. Roche pays the Menlo Park, CA, company $35 million up front but will fork over up to $40 million more as developmental milestones are met. Pacific Biosciences will develop and make gene sequencing and other clinical products and license them exclusively to Roche. Roche, in turn, gains exclusive global rights to sell the products for human in vitro diagnostics. Pacific Biosciences is known for creating cutting-edge technology designed to quickly and cheaply decode DNA. FierceBiotech | FierceDiagnostics

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.